Needham Believes Corium (NASDAQ: CORI) Still Has Room to Grow

By Jason Carr

Needham analyst Alan Carr reiterated a Buy rating on Corium (NASDAQ: CORI) on September 15 and set a price target of $13. The company’s shares closed on Friday at $9.91, close to its 52-week high of $10.35.

According to TipRanks.com, Carr is a 4-star analyst with an average return of 7.3% and a 44.3% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Corium has an analyst consensus of Strong Buy, with a price target consensus of $12.

The company has a one year high of $10.35 and a one year low of $2.67. Currently, Corium has an average volume of 202.5K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CORI in relation to earlier this year. Last month, Peter Staple, the President & CEO of CORI bought 50,000 shares for a total of $106,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes of specialty pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1995 and is headquartered in Menlo Park, CA.